Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial.
- DOI
- 10.1136/bmjophth-2023-001561
- Published
- 2023 Dec 19
- Container
- BMJ open ophthalmology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/bmjophth-2023-001561,
title = {Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial.},
author = {Sadda SR and Bradvica M and Vajas A and Sagong M and Ernest J and Studnička J and Veith M and Wylegala E and Patel S and Yun C and Orski M and Astakhov S and Tóth-Molnár E and Csutak A and Enyedi L and Choi W and Oh I and Jang H and Woo SJ},
year = {2023},
journal = {BMJ open ophthalmology},
doi = {10.1136/bmjophth-2023-001561},
url = {https://doi.org/10.1136/bmjophth-2023-001561}
}RIS
TY - JOUR TI - Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial. AU - Sadda SR AU - Bradvica M AU - Vajas A AU - Sagong M AU - Ernest J AU - Studnička J AU - Veith M AU - Wylegala E AU - Patel S AU - Yun C AU - Orski M AU - Astakhov S AU - Tóth-Molnár E AU - Csutak A AU - Enyedi L AU - Choi W AU - Oh I AU - Jang H AU - Woo SJ PY - 2023 JO - BMJ open ophthalmology DO - 10.1136/bmjophth-2023-001561 UR - https://doi.org/10.1136/bmjophth-2023-001561 ER -
APA
SR, S., M, B., A, V., M, S., J, E., J, S., M, V., E, W., S, P., C, Y., M, O., S, A., E, T., A, C., L, E., W, C., I, O., H, J., & SJ, W. (2023). Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial.. BMJ open ophthalmology. https://doi.org/10.1136/bmjophth-2023-001561
Source records
- pubmed · retrieved 2026-09-26T15:00:07.617Z
- europe-pmc · retrieved 2026-09-26T15:00:07.619Z
- doaj · retrieved 2026-09-26T15:00:07.606Z